.png)
Onco-Summaries: Daily Oncology Updates at a Glance
- Oncofocus Team
- 2 days ago
- 2 min read
02/04/2026
Merck & Co./MSD's pembrolizumab + paclitaxel ± bevacizumab received the EC approval for Platinum-Resistant Recurrent Ovarian Carcinoma (Ref)
The EC approved Merck & Co./MSD's pembrolizumab (anti-PD-1) + paclitaxel ± bevacizumab for the treatment of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma in adults with PD-L1 CPS ≥1, and who have received one or two prior systemic treatment regimens.
This approval also covers the subcutaneous product KEYTRUDA SC
This approval is based on results from the Phase 3 KEYNOTE-B96 trial
Context Therapeutics' CTIM-76 received the FDA fast track designation for platinum-resistant ovarian cancer (Ref)
The US FDA granted the fast track designation to Context Therapeutics' CTIM-76 (CLDN6 x CD3 T cell engaging bispecific antibody) for the treatment of platinum-resistant ovarian cancer in patients that have received all standard of care therapies.
Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers
AstraZeneca's Phase 3 EMERALD-3 trial met the PFS endpoint in embolisation-eligible unresectable HCC (Ref)
AstraZeneca's Phase 3 EMERALD-3 trial of durvalumab (anti-PD-L1) + tremelimumab (anti-CTLA-4) + lenvatinib + TACE demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS vs TACE alone for patients with unresectable hepatocellular carcinoma eligible for embolisation.
At this interim analysis for OS (key secondary endpoint), the combination also demonstrated a trend toward OS improvement vs TACE alone
The safety profile for each combination was consistent with the known profiles of each medicine, and there were no new safety findings
Comments